FDA to review Tarceva as a pancreatic cancer treatment
Tarceva is an oral tablet indicated for daily administration in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.